Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Galectin-1 binds to influenza virus and ameliorates influenza virus pathogenesis.

Yang ML, Chen YH, Wang SW, Huang YJ, Leu CH, Yeh NC, Chu CY, Lin CC, Shieh GS, Chen YL, Wang JR, Wang CH, Wu CL, Shiau AL.

J Virol. 2011 Oct;85(19):10010-20. doi: 10.1128/JVI.00301-11. Epub 2011 Jul 27.

2.

Desialylation of airway epithelial cells during influenza virus infection enhances pneumococcal adhesion via galectin binding.

Nita-Lazar M, Banerjee A, Feng C, Amin MN, Frieman MB, Chen WH, Cross AS, Wang LX, Vasta GR.

Mol Immunol. 2015 May;65(1):1-16. doi: 10.1016/j.molimm.2014.12.010. Epub 2015 Jan 16.

3.

Antiviral activity of the long chain pentraxin PTX3 against influenza viruses.

Reading PC, Bozza S, Gilbertson B, Tate M, Moretti S, Job ER, Crouch EC, Brooks AG, Brown LE, Bottazzi B, Romani L, Mantovani A.

J Immunol. 2008 Mar 1;180(5):3391-8.

4.

Saikosaponin A inhibits influenza A virus replication and lung immunopathology.

Chen J, Duan M, Zhao Y, Ling F, Xiao K, Li Q, Li B, Lu C, Qi W, Zeng Z, Liao M, Liu Y, Chen W.

Oncotarget. 2015 Dec 15;6(40):42541-56. doi: 10.18632/oncotarget.6448.

5.

L-ficolin binds to the glycoproteins hemagglutinin and neuraminidase and inhibits influenza A virus infection both in vitro and in vivo.

Pan Q, Chen H, Wang F, Jeza VT, Hou W, Zhao Y, Xiang T, Zhu Y, Endo Y, Fujita T, Zhang XL.

J Innate Immun. 2012;4(3):312-24. doi: 10.1159/000335670. Epub 2012 Mar 2.

6.

H5N1 influenza virus pathogenesis in genetically diverse mice is mediated at the level of viral load.

Boon AC, Finkelstein D, Zheng M, Liao G, Allard J, Klumpp K, Webster R, Peltz G, Webby RJ.

MBio. 2011 Sep 6;2(5). pii: e00171-11. doi: 10.1128/mBio.00171-11. Print 2011.

7.

Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection.

Prabhu N, Prabakaran M, Ho HT, Velumani S, Qiang J, Goutama M, Kwang J.

J Virol. 2009 Mar;83(6):2553-62. doi: 10.1128/JVI.02165-08. Epub 2008 Dec 24.

8.

Visualizing influenza virus infection in living mice.

Pan W, Dong Z, Li F, Meng W, Feng L, Niu X, Li C, Luo Q, Li Z, Sun C, Chen L.

Nat Commun. 2013;4:2369. doi: 10.1038/ncomms3369.

9.

Influenza A Virus Protein PA-X Contributes to Viral Growth and Suppression of the Host Antiviral and Immune Responses.

Hayashi T, MacDonald LA, Takimoto T.

J Virol. 2015 Jun;89(12):6442-52. doi: 10.1128/JVI.00319-15. Epub 2015 Apr 8.

10.

Intratracheal administration of influenza virus is superior to intranasal administration as a model of acute lung injury.

Morales-Nebreda L, Chi M, Lecuona E, Chandel NS, Dada LA, Ridge K, Soberanes S, Nigdelioglu R, Sznajder JI, Mutlu GM, Budinger GR, Radigan KA.

J Virol Methods. 2014 Dec;209:116-20. doi: 10.1016/j.jviromet.2014.09.004. Epub 2014 Sep 17.

11.

17β-estradiol protects females against influenza by recruiting neutrophils and increasing virus-specific CD8 T cell responses in the lungs.

Robinson DP, Hall OJ, Nilles TL, Bream JH, Klein SL.

J Virol. 2014 May;88(9):4711-20. doi: 10.1128/JVI.02081-13. Epub 2014 Feb 12.

12.

Combined administration of oseltamivir and hochu-ekki-to (TJ-41) dramatically decreases the viral load in lungs of senescence-accelerated mice during influenza virus infection.

Ohgitani E, Kita M, Mazda O, Imanishi J.

Arch Virol. 2014 Feb;159(2):267-75. doi: 10.1007/s00705-013-1807-3. Epub 2013 Aug 25.

PMID:
23979178
13.

The role of interferon in influenza virus tissue tropism.

García-Sastre A, Durbin RK, Zheng H, Palese P, Gertner R, Levy DE, Durbin JE.

J Virol. 1998 Nov;72(11):8550-8.

14.

FimH, a TLR4 ligand, induces innate antiviral responses in the lung leading to protection against lethal influenza infection in mice.

Abdul-Careem MF, Firoz Mian M, Gillgrass AE, Chenoweth MJ, Barra NG, Chan T, Al-Garawi AA, Chew MV, Yue G, van Roojen N, Xing Z, Ashkar AA.

Antiviral Res. 2011 Nov;92(2):346-55. doi: 10.1016/j.antiviral.2011.09.004. Epub 2011 Sep 14.

PMID:
21945041
15.

A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice.

Bantia S, Kellogg D, Parker C, Upshaw R, Ilyushina NA, Babu YS.

Antiviral Res. 2011 Apr;90(1):17-21. doi: 10.1016/j.antiviral.2011.02.001. Epub 2011 Feb 21.

PMID:
21316393
16.

Influenza A virus-induced degradation of eukaryotic translation initiation factor 4B contributes to viral replication by suppressing IFITM3 protein expression.

Wang S, Chi X, Wei H, Chen Y, Chen Z, Huang S, Chen JL.

J Virol. 2014 Aug;88(15):8375-85. doi: 10.1128/JVI.00126-14. Epub 2014 May 14.

17.

Inhaled nitric oxide therapy fails to improve outcome in experimental severe influenza.

Darwish I, Miller C, Kain KC, Liles WC.

Int J Med Sci. 2012;9(2):157-62. doi: 10.7150/ijms.3880. Epub 2012 Jan 13.

18.

In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections.

Kumaki Y, Day CW, Smee DF, Morrey JD, Barnard DL.

Antiviral Res. 2011 Nov;92(2):329-40. doi: 10.1016/j.antiviral.2011.09.001. Epub 2011 Sep 8.

19.

The effect of rosuvastatin in a murine model of influenza A infection.

Radigan KA, Urich D, Misharin AV, Chiarella SE, Soberanes S, Gonzalez A, Perlman H, Wunderink RG, Budinger GR, Mutlu GM.

PLoS One. 2012;7(4):e35788. doi: 10.1371/journal.pone.0035788. Epub 2012 Apr 20.

20.

Amelioration of influenza virus-induced reactive oxygen species formation by epigallocatechin gallate derived from green tea.

Ling JX, Wei F, Li N, Li JL, Chen LJ, Liu YY, Luo F, Xiong HR, Hou W, Yang ZQ.

Acta Pharmacol Sin. 2012 Dec;33(12):1533-41. doi: 10.1038/aps.2012.80. Epub 2012 Sep 3.

Supplemental Content

Support Center